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Original article
Magnetic resonance imaging in the diagnosis
of white matter signal abnormalities
Ravi Datar1,2, Asuri Narayan Prasad1,3,4,5, Keng Yeow Tay1,6,
Charles Anthony Rupar1,3,5,7,8, Pavlo Ohorodnyk6, Michael Miller3,5
and Chitra Prasad1,3,5
Abstract
Background: White matter abnormalities (WMAs) pose a diagnostic challenge when trying to establish etiologic diagnoses.
During childhood and adult years, genetic disorders, metabolic disorders and acquired conditions are included in differ-
ential diagnoses. To assist clinicians and radiologists, a structured algorithm using cranial magnetic resonance imaging
(MRI) has been recommended to aid in establishing working diagnoses that facilitate appropriate biochemical and genetic
investigations. This retrospective pilot study investigated the validity and diagnostic utility of this algorithm when applied to
white matter signal abnormalities (WMSAs) reported on imaging studies of patients seen in our clinics.
Methods: The MRI algorithm was applied to 31 patients selected from patients attending the neurometabolic/neurogenetic/
metabolic/neurology clinics at a tertiary care hospital. These patients varied in age from 5 months to 79 years old, and were
reported to have WMSAs on cranial MRI scans. Twenty-one patients had confirmed WMA diagnoses and 10 patients had
non-specific WMA diagnoses (etiology unknown). Two radiologists, blinded to confirmed diagnoses, used clinical abstracts
and the WMSAs present on patient MRI scans to classify possible WMA diagnoses utilizing the algorithm.
Results: The MRI algorithm displayed a sensitivity of 100%, a specificity of 30.0% and a positive predicted value of 74.1%.
Cohen’s kappa statistic for inter-radiologist agreement was 0.733, suggesting ‘‘good’’ agreement between radiologists.
Conclusions: Although a high diagnostic utility was not observed, results suggest that this MRI algorithm has promise as a
clinical tool for clinicians and radiologists. We discuss the benefits and limitations of this approach.
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Introduction
A key feature of the developing brain is myelination
progression in the central nervous system, starting as
early as 25 weeks into fetal development.1 Central mye-
linogenesis requires an intricate partnership between
axons and the oligodendrocytes responsible for myelin
deposition and maintenance.2 Dysfunction of either of
these cell types at any of the various levels of myelin
biosynthesis and turnover can lead to diseases of cra-
nial white matter and consequential functional impair-
ments that can lead to progressive neurological disease
and eventually death.3
The clinical diagnosis of such white matter abnorm-
alities (WMAs) continues to be of utmost importance.4
On cranial imaging studies, such as magnetic resonance
imaging (MRI), WMAs can be identified by the pres-
ence of visible white matter signal abnormalities
(WMSAs). A major consideration in these settings is
a group of disorders called leukoencephalopathies
(LEs; see Figure 1). LEs, a term applying to all brain
WMAs, can be inherited or acquired. Limited
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treatment options add to their severity and burden of
disease.5 As these disorders pose a diagnostic challenge
and are time sensitive, attention has been focused on
shortening the time to diagnosis and improving phys-
ician awareness. The reported prevalence of WMAs
varies in the literature across different age groups and
geographies. Leukodystrophies (LDs; see Figure 2)
are a form of inherited LEs, and the reported preva-
lence of all major forms of LDs varies from 1/50,000 in
Germany6 to 1/7663 in Utah, United States.7 However,
WMAs are being recognized and reported more often
in young children.7
The appropriate diagnosis of WMAs in infants and
children is particularly crucial given high mortality
rates for inherited progressive LDs; 85% to 90% of
infants suffering from a disease such as Krabbe disease
die before 2 years of age.8 The earlier the diagnosis and
management of the few treatable WMAs, the better the
outcome is for subsequent myelin deposition.9
Organizations such as the Global Leukodystrophy
Initiative have underscored the fact that despite being
members of the Society of Inherited Metabolic
Disorders and the Child Neurology Society, most bio-
chemical/clinical geneticists and pediatric neurologists
find it challenging to provide differential diagnoses of
some WMAs.10
A recent clinician survey suggested that only 52% of
clinicians are at least moderately confident of providing
a WMA diagnosis, with only 16% of clinicians being
highly confident.10 Symptoms of different diseases often
overlap and present similarly in the clinic, contributing
to the difficulty of establishing a differential diagnosis.11
Nonetheless, there are a few WMAs that are associated
with specific clinical features that can carry diagnostic
value.12 These can be quite helpful when a clinician
attempts to narrow down a differential diagnosis,
such as the presence of adrenal insufficiency in patients
with adrenoleukodystrophies.10
In recent years, authorities in the field of LEs have
suggested that cranial MRI scans can strongly aid an
accurate diagnosis of WMAs through a systematic ana-
lysis of the WMSAs present on scans.10,12 A protocol
has been proposed that uses cranial MRI analysis as a
keystone in the diagnostic algorithm to expedite the
diagnosis of WMAs.10,12 Different imaging sequences,
such as T1-weighted (T1W), T2-weighted (T2W) and
fluid-attenuated inversion recovery (FLAIR) signals
vary in their sensitivity to different structural compo-
nents in brain matter, which can be analyzed to create
characteristic patterns for certain categories of WMAs.
The diagnostic algorithm provides clinicians with a
step-by-step approach to narrowing down a patient’s
diagnosis to a group of diseases that exhibit WMSA
similarities on MRI scans.10,12 This algorithm takes
into consideration the type of myelin pathology (hypo-
myelination, demyelination, delayed myelination and
dysmyelination) as well as the location, symmetry,
regional distribution, signal intensity and change over
time of the WMSAs to categorize certain WMAs.10
Authors of this approach have statistically validated
the categorization of WMAs based on WMSA patterns
in their clinics.13 Through the application of the algo-
rithm, recognition of WMSA patterns can lead to a
Figure 1. Axial fluid-attenuated inversion recovery magnetic res-
onance imaging scan of the brain showing extensive white matter
hyperintensity extending to the subcortical U-fibers. The central
white matter suppresses with signal similar to cerebrospinal fluid
(see white arrows) in this patient with vanishing white matter
disease.
Figure 2. Axial T2-weighted magnetic resonance imaging scan of
the brain showing the ‘‘tigroid’’ pattern (white arrow) often seen
in metachromatic leukodystrophy.
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group of differential diagnoses after consideration of
the patient’s clinical data. A clinician can then order
a focused set of molecular genetic testing for these diag-
nostic shortlists, rather than subjecting the patient to a
larger set of tests that can be expensive, demanding on
the patient and sometimes inconclusive.12,14
At the London Health Sciences Centre in London,
Ontario, Canada, approximately 270 patients of
varying ages have been diagnosed with WMAs via
confirmative genetic/biochemical testing since 2004.
The primary objective of this study is to evaluate the
utility of such a diagnostic system, with the goal of
raising physician awareness and implications for
wider clinical use. It is worth investigating this
MRI-centric algorithm for three main reasons: (a) the
current lack of a systematic diagnostic approach to
WMSAs, (b) the high mortality rate and short life
expectancies associated with some WMAs and (c) the
potential to improve the accuracy and shorten time to
WMA diagnosis.15 This project aims to study the utility
of the algorithm in deducing WMA diagnoses as well as
its reliability between multiple algorithm users. We
hypothesized that this MRI algorithm would display
diagnostic utility as a test with both high accuracy
and inter-rater reliability.
Methods
Participant selection criteria
A total of 270 patients in the neurometabolic/neuroge-
netic/metabolic/neurology clinics were sequentially
assessed for inclusion. The patients included in this
study were referred to these clinics at the London
Health Sciences Centre in London, Ontario, Canada,
between 2004 and 2015. These patients completed a
consultation and at least one cranial MRI scan.
The MRI scans for these patients were confirmed by
a neurologist as displaying WMSAs.
In the selection process, some patients were excluded
on the basis that their WMSAs were not attributed pri-
marily to WMAs, but rather to other factors such as
acute trauma. After applying the above-mentioned
selection criteria, 31 patients (14 males, 17 females)
were selected for this study. The ages of the patients
ranged from five months to 79 years. Twenty-one
patients had a specific diagnosis for their WMAs
based on confirmative molecular and biochemical test-
ing, and 10 had non-specific WMAs (i.e. non-confirma-
tive based on clinical assessment supported by negative
molecular/biochemical test results). For purposes of
patient confidentiality, all patients were anonymized
and given a numerical code. Identifiable patient infor-
mation and corresponding numerical codes were stored
on a virtual password-protected document, which was
accessible only by the principal investigator (CP) and
student researcher (RD). Patients’ dates of birth were
the only personal information disclosed to the entire
research team. This study was approved by the
Health Sciences Research Ethics Board at Western
University, London, Ontario, Canada.
Diagnostic algorithm
The first phase of this study involved an independent
analysis of all cranial MRI scans by two radiologists,
yielding two sets of data for each patient. For each
scan, the radiologists were given the dates when scans
were performed since myelination progress is age
dependent.
The radiologists included in this study, KYT and
PO, had 11 years and one year of experience respect-
ively at the time of MRI scan interpretation. After ana-
lysis of T1W, T2W and FLAIR signals, the radiologists
deduced the type of myelin pathology as shown in the
scans (see Figure 3; readers interested in reviewing more
images are invited to reference Schiffman and van der
Knaap, 200914). The first point of determination was
establishing the presence/absence of hypomyelination.
If the radiologists observed a hypomyelination pattern
present on the scans, they proceeded to look at
WMSAs in the cerebellum, the basal ganglia and the
presence/absence of global atrophy to determine the
subtype of hypomyelination present. After determining
this, the radiologists arrived at a category of WMAs. In
case there was no hypomyelination pattern present, the
radiologists analyzed the MRI scan for the location,
symmetry and regional distribution/isolation of the
WMSAs. This was performed to confirm the presence
of dysmyelination or demyelination and to arrive at a
specific group of WMAs with shared characteristics.
Once the radiologists had arrived at a particular
group of conditions, they were given abstracted clinical
data including both neurological and extra-neurologi-
cal symptoms. Using this clinical information, the radi-
ologists were asked to reduce the group of conditions in
a particular category to one to three differential diag-
noses of the patient’s WMA. With each differential
diagnosis, the radiologists were asked to associate a
level of confidence from 1 to 10 with 1 being not con-
fident and 10 being very confident. A confidence value
of 4 was selected as the threshold; in a clinical scenario,
a differential diagnosis with such a low likelihood is
unlikely to be considered. Thus, any differential diag-
nosis with a confidence value 4 was discarded. If the
WMSAs were unable to fit into the algorithm and the
radiologists were unable to reach a category, a non-
specific diagnosis was recorded.
The WMSAs in the MRI scans were either diagnos-
tic of a specific genetic/acquired condition (molecular/
biochemical testing was positive) or non-specific
(molecular/biochemical testing was negative). For all
patients, the radiologists were blinded to the confirmed
diagnosis, or ‘‘correct answer.’’ Based on whether the
algorithm correctly deduced confirmed specific
diagnoses or non-specific diagnosis when molecular/
biochemical tests were actually positive, values for
true-positive and false-negative (respectively) outcomes
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were recorded. On the other hand, if the
algorithm results were inconclusive of a diagnosis for
confirmed non-specific WMAs or suggested a diagnosis
when molecular/biochemical tests were actually
negative, values for true-negative or false-positive
(respectively) outcomes were recorded. All statistical
analyses were performed using GraphPad Prism 6
software. The positive/negative testing outcomes
allowed for sensitivity, specificity and positive predict-
ive value (PPV) statistics, which were used to determine
the utility of the algorithm in diagnosing WMAs.
Cohen’s kappa statistic was used to quantify algorithm
consistency in terms of inter-rater agreement between
the radiologists’ outcomes.
Results
Data collection was performed over the span of seven
months at the radiology department at Children’s
Hospital in London, Ontario, Canada. Both radiolo-
gists expressed concerns with isolating one to three dif-
ferential diagnoses from the specified category. Since
the professional responsibilities of radiologists do not
include diagnosing a patient, but rather solely identify-
ing patterns in an MRI scan, their evaluation of differ-
ential diagnoses was not considered an accurate
representation of the algorithm’s validity. Thus, all
test outcomes were based on whether the algorithm
allowed the radiologists to arrive at the correct category
rather than the correct differential diagnoses within
the category.
Although this study began with 31 patients, patient
018 was excluded from this study after data collection
(see Table 1). Both radiologists felt that the algorithm
was not applicable for this patient. They were unable to
deduce hypomyelination, as there was only one set of
images available for the patient rather than sequential
scans at least six months apart. With the exclusion of
this patient, the final sample consisted of 30 patients,
and the prevalence of specific confirmed diagnoses
was 66.7%.
Table 2 summarizes these diagnostic outcomes and
whether each positive/negative conclusion was correct
(true) or incorrect (false).
The diagnostic utility of this clinical diagnostic
algorithm was quantified through four statistics: sensi-
tivity, specificity, the PPV and Cohen’s kappa statistic.
Sensitivity was used as a measure of the algorithm to
correctly identify patients with a specific diagnosis.16
Specificity was used to correctly identify patients with
a non-specific diagnosis.16 The PPV was used to quan-
tify the proportion of all specific diagnoses produced by
the algorithm in which the suggested category correctly
contained the confirmed diagnosis.16 Cohen’s kappa
statistic was used to determine inter-rater reliability.
Sensitivity, specificity and PPV values are summar-
ized in Table 3. Both radiologists successfully recog-
nized a specific diagnosis for all specifically diagnosed
patients (i.e. recorded no false-negatives). Hence, the
individual and mean sensitivity and negative predictive
value (NPV) of the algorithm was 100% for this patient
sample. The ability of the algorithm to identify
non-specific diagnoses as non-specific via the algorithm,
however, was much lower at a mean specificity of
30.0%. The mean PPV was calculated as 74.1%,
implying that for every four patients for whom a cat-
egory was reached, approximately three of these
patients had a confirmed specific diagnosis. Out of all
Figure 3. Fluid-attenuated inversion recovery (left) and T2-weighted (right) magnetic resonance imaging scans for patient 013. Using the
algorithm, both radiologists confirmed a non-hypomyelination pattern. Multifocal white matter signal abnormalities (WMSAs) were noted
(see white arrows for a focus). These WMSAs progressed to confluence over seven years of longitudinal scans. After progressing through
the algorithm, both radiologists used this information to arrive at category 7.17 (true positive outcome). This category correctly included
the confirmed differential diagnosis of Fabry disease.
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the true-positive outcomes produced by the radiolo-
gists, they did not always reach a category that con-
tained the correct differential diagnosis. For all true-
positives, an accurate category was reached on average
62.5% of the time (Radiologist 1 – 75% and
Radiologist 2 – 50%). The calculated Cohen’s kappa
was 0.733 (see Table 4), suggesting good agreement
between the radiologists.17
Discussion
It was originally hypothesized that the MRI algorithm
would yield diagnostic utility as a test with high
Table 1. Summary of diagnostic outcomes after the analysis of 31 patients with WMAs.
Patient ID Confirmed diagnosis
Radiologist 1
outcome
Radiologist 2
outcome
001 MELAS TP TP
002 Vanishing white matter disease TP TP
003 Phenylketonuria TP TP
004 Adrenomyeloneuropathy with adrenal insufficiency TP TP
005 Multiple sulfatase deficiency TP TP
006 Leigh syndrome TP TP
007 Fabry disease TP TP
008 Phenylketonuria TP TP
009 Neuronal ceroid lipofuscinosis TP TP
010 MELAS TP TP
011 5MTHFR deficiency TP TP
012 X-linked adrenoleukodystrophy TP TP
013 Fabry disease TP TP
014 Metachromatic leukodystrophy TP TP
015 MELAS TP TP
016 CADASIL TP TP
017 NARP-like mitochondrial disorder TP TP
018a Coffin-Siris syndrome TP FN
019 Krabbe disease TP TP
020 48, XXXY syndrome TP TP
021 GMI gangliosidosis TP TP
022 NON-SPECIFIC FP FP
023 NON-SPECIFIC TN FP
024 NON-SPECIFIC FP FP
025 NON-SPECIFIC FP FP
026 NON-SPECIFIC TN TN
027 NON-SPECIFIC TN FP
028 NON-SPECIFIC TN FP
029 NON-SPECIFIC FP FP
030 NON-SPECIFIC TN FP
031 NON-SPECIFIC FP FP
Patients 001–021 have been diagnosed with a specific WMA and patients 022–031 have been non-specifically diagnosed (etiology
unknown). Values shown include true positive (TP), true negative (TN), false positive (FP) and false negative (FN). Outcomes are
presented by individual radiologist. aPatient 018 was excluded from the study and subsequent statistical analysis, thus altering the
prevalence of a specific diagnosed condition to 66.7%. CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; ID: identification; MELAS: mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes;
WMAs: white matter abnormalities.
Table 2. Summary of diagnostic outcomes after the analysis of 30
patients by two radiologists using the MRI algorithm.
TP FP TN FN
Radiologist 1 20 5 5 0
Radiologist 2 20 9 1 0
TOTAL 40 14 6 0
Twenty patients were diagnosed with a specific WMA and 10 were given
non-specific diagnoses (etiology unknown). Prevalence of a specific diag-
nosed condition was 66.7%. Values shown include true positive (TP), true
negative (TN), false positive (FP) and false negative (FN). Outcomes are
presented by individual radiologist and as combined totals. MRI: magnetic
resonance imaging; WMA: white matter abnormality.
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accuracy and inter-rater reliability. The perfect sensitiv-
ity and NPVs of this algorithm can be attributed to the
lack of any false-negatives diagnostic outcomes. For
patients with a specific confirmed diagnosis, the radi-
ologists always arrived at a category and, thus, pro-
duced a true-positive outcome. A perfect sensitivity
and low specificity have the implication of producing
occasional false-positives, which was seen in this group
of diagnostic outcomes. Sensitivity takes into consider-
ation only whether a category is reached, but not
whether the category is the one containing the correct
diagnosis. The latter is a better measure of utility for
clinicians, as reaching a working category that omits
the correct differential diagnosis is of no benefit. For
all true positives, a correct differential diagnosis-con-
taining category was reached 62.5% of the time. This
statistic combined with the lower specificity and PPV
values downplay the utility of the algorithm. The low
specificity suggests that specific outcomes were overpro-
duced, i.e. even those WMSAs that were due to non-
specific WMAs were incorrectly categorized into spe-
cific categories. This can be considered a limitation of
the study and the utility of the algorithm may be
dependent on the individuals who are using it, the
nature of imaging findings and the timing/availability
of sequential scans. Certain patients, however, dis-
played WMSAs that were characteristic enough to fit
into the algorithm. The nature of these WMSAs to
manifest similarly to WMSAs of a specific diagnosis
contributed to the algorithm’s lower responsiveness to
non-specific WMAs.
Specificity and PPV values varied substantially
between the two radiologists (50.0% vs. 10.0% and
80.0% vs. 69.0%, respectively). A Cohen’s kappa
statistic of 0.733 suggests a ‘‘good’’ level of agreement
between the two radiologists. Considering that there
were only two raters in this study, however, it is uncer-
tain whether these values would change if a larger
group of radiologists were consulted. The radiologists
also varied in their levels of training; one consultant
was an attending neuroradiologist with many years of
diagnostic experience and the other consultant was a
recent neuroradiology fellow. This difference in experi-
ence may have also contributed to a difference in diag-
nostic outcomes. It would be prudent to include >2
radiologists in future investigations for a more represen-
tative assessment of the algorithm’s inter-rater reliability,
accuracy and to produce narrower confidence intervals.
A decision tree representation of the algorithm is
shown (Figure 4) in which the first decision to be
made is whether hypomyelination or another myelin
pathology is present. Hypomyelination is a term
reserved for WMAs that have a significant and perman-
ent deficit in the deposition of myelin.9 To confirm the
permanent nature of the myelin deficit, MRI scans must
be viewed longitudinally. Hypomyelination requires
multiple sequential MRI scans that are a minimum of
six months apart.9 Without these sequential scans, there
are insufficient data to distinguish between hypomyeli-
nation and delayed myelination, the latter of which is
not permanent and improves over time.10 This multiple
sequential imaging requirement should be emphasized
in future investigations.
During data collection, it was noted that the
algorithm was not able to distinguish WMAs that had
been well managed early on in life. Phenylketonuria is a
disorder that can be detected in newborn screening, and
Table 3. Summary of diagnostic statistics after the analysis of 30 patients by two radiologists using
the MRI algorithm. Sensitivity¼ TP/(TPþ FN); Specificity¼ TN/(TNþ FP); PPV¼ TP/(TPþ FP);
NPV¼ TN/(TNþ FP). Point estimates are followed by 95% confidence intervals in brackets.
Sensitivity Specificity PPV NPV
Radiologist 1 100 (–) 50.0 (19.0–81.0) 80.0 (64.3–95.7) 100 (–)
Radiologist 2 100 (–) 10.0 (-8.59–28.6) 69.0 (52.1–85.8) 100 (–)
MEAN 100 (–) 30.0 (1.60–58.4) 74.1 (57.5–90.6) 100 (–)
Twenty patients were diagnosed with a specific WMA and 10 were given non-specific diagnoses (etiology unknown).
Prevalence of a specific diagnosed condition was 66.7%. Values shown include true positive (TP), true negative (TN),
false positive (FP) and false negative (FN). Outcomes are presented by individual radiologist and as combined totals.
MRI: magnetic resonance imaging; NPV: negative predictive value; PPV: positive predictive value; WMA: white matter
abnormality.
Table 4. Summary of paired outcomes provided by both radiolo-
gists on a patient-by-patient basis. The top row refers to the
diagnostic outcome (TP/FP/TN/FN) from the first radiologist. The
left column refers to the diagnostic outcome (TP/FP/TN/FN) from
the second radiologist. From this tabulation, the observed kappa
statistic was calculated via GraphPad Prism 6 software as 0.733.
Radiologist 1
TP FP TN FN
Radiologist 2 TP 20 0 0 0
FP 0 5 4 0
TN 0 0 1 0
FN 0 0 0 0
Twenty patients were diagnosed with a specific WMA and 10 were given
non-specific diagnoses (etiology unknown). Prevalence of specific diag-
nosed condition was 66.7%. Shaded boxes indicate instances where both
radiologists were in agreement. FN: false negative; FP: false positive; MRI:
magnetic resonance imaging; TN: true negative; TP: true positive; WMA:
white matter abnormality.
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the consistent following of a low-phenylalanine diet can
result in a very normal phenotype. Similarly, Fabry dis-
ease can have variable neurological presentations.
Individuals with well-managed diseases can have dimin-
ished severity of abnormalities seen on MRI scans. The
algorithm demands for distinct, distinguishable WMSA
patterns, and the absence of such patterns, makes it dif-
ficult for the algorithm to sense well-managed WMAs.
The algorithm also displayed difficulties with end-
stage WMAs. After a certain amount of time and dis-
ease progression, WMSAs become so severe on MRI
scans that the originally distinguishable patterns
Figure 4. The magnetic resonance imaging (MRI) algorithm used for the analysis of white matter signal abnormalities (WMSAs) on
patient cranial scans. The radiologist began by identifying whether the signal abnormality was indicative of hypomyelination or another
type of myelin pathology (dysmyelination, demyelination, etc.). Within the type of myelination present, the radiologist proceeded through
the algorithm down the paths that were most applicable to the WMSAs on the scans. Once at a concluding category, denoted by 7.##, the
radiologist consulted the patient clinical data to determine differential diagnoses contained in that numerical category. Up to three
possible differential diagnoses were allowed for each patient. For each differential diagnosis, a confidence value of 1–10 was assigned.
This algorithm, the categorical organization and legend abbreviations are identical to those published by Parikh et al., but the pre-
sentation is different.10
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homogenize across different diseases. WMSAs that
manifest in different locations can eventually progress
to confluence and invade most of the brain tissue. In
these scenarios, properties that the algorithm requires
(e.g. primary WMSA location, isolation and signal
intensity) are lost, and the algorithm is not diagnostic-
ally valuable. These limitations stress the need for early
MRI scans in the clinical implications of the algorithm,
which is supported by these data.
Since the day-to-day professional responsibilities of
radiologists do not include determining differential
diagnoses but rather solely identifying WMSA patterns
on MRI scans, relying on radiologists alone may be
insufficient for clinical applications. The algorithm
would likely display a higher utility if other clinicians
such as genetic/metabolic/neurological specialists also
provided ratings. Realistic usage of this algorithm
would involve radiologists concluding a category of
WMAs with commonly manifesting WMSAs on cranial
MRI scans and other clinicians using clinical abstrac-
tions to narrow this category into differential diagnoses,
thus close collaboration between neuroradiologists and
genetic/metabolic/neurologist physicians is helpful.
Without MRI emphasis, some WMAs may require
sequential molecular testing using targeted LD/LE gene
panels that are commercially available. If these panels
LEGEND: 
4H: hypomyelination, hypodontia and hypogonadotropic hypogonadism 
ADLD: autosomal dominant leukodystrophy with autonomic symptoms
APBD: adult polyglucosan body disease 
BCAA: branched-chain amino acid 
CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CARASIL: cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CMV: cytomegalovirus 
CRMCC: cerebroretinal microangiopathy with calcifications and cysts 
CTX: cerebrotendinous xanthomatosis 
DRPLA: dentatorubral-pallidoluysian atrophy 
EIF2B-related disorders: vanishing white matter disease or childhood ataxia with 
diffuse CNS hypomyelination) 
HABC: hypomyelination with atrophy of the basal ganglia and cerebellum 
HBSL: hypomyelination with brainstem and spinal cord involvement and leg spasticity
HCC: hypomyelination with congenital cataract 
HDLS: hereditary diffuse leukoencephalopathy with spheroids 
HEMS: hypomyelination of early myelinating structures 
HIV: human immunodeficiency virus 
LBSL: leukoencephalopathy with brainstem and spinal cord involvement and lactate 
elevation 
LD: leukodystrophy 
LE: leukoencephalopathy 
LTBL: leukoencephalopathy with thalamus and brainstem involvement and high 
lactate 
MLC: megalencephalic leukoencephalopathy with subcortical cysts 
MPS: mucopolysaccharidoses 
MSUD: maple syrup urine disease 
NCL: neuronal ceroid lipofuscinosis 
ODDD: oculodentodigital dysplasia 
PKU: phenylketonuria 
PMD: Pelizaeus-Merzbacher disease 
PMLD: Pelizaeus-Merzbacher like-disease 
X-ALD: X-linked adrenoleukodystrophy 
6.75.74.73.72.71.7
SOX10 related 
disorders 
MCT8 related 
disorders 
Other neuronal 
disorders 
4H syndrome 
HABC 
ODDD 
Salla disease 
Cockayne syndrome 
Fucosidosis 
HABC 
ODDD 
Mucolipidosis 
type IV 
18q minus syndrome 
HCC (N.B. some regions 
may have low T1 signal 
HEMS 
PMD 
PMLD 
Salla disease 
SOX10-associated 
disorders 
Infantile Sialic 
Acid Storage 
Disease 
Aicardi-
Goutieres 
syndrome 
Serine synthesis defects 
NCL 
Early onset GM1 and GM2 
Mitochondrial disorders 
Fumarate Hydratase deficiency 
Band-like intracranial calcification with sim. 
gyration and polymicroglia 
Neuropathic form of malignant infantile 
osteopetrosis 
AGC1-rel disorders 
HSPD1-rel disorders 
AIMP1-rel disorders 
GPR56-rel disorders 
21.711.701.79.78.77.7
18q minus 
syndrome 
HCC 
Galactosemia 
type I 
Adenylosuccinate 
lyase deficiency 
Aspartylglucos-
aminuria 
GPR56 related 
disorders 
Dystrogly-
canopathies 
D-2-
hydroxyglutaric 
aciduria 
MLC 
elF2B related disorder 
Laminin alpha-2 
deficiency 
Some mitochondrial 
defects 
Inborn errors of 
metabolism (including 
Molybdenum cofactor 
deficiency, glutaric aciduria 
II, dihydropterine reductase 
deficiency, BCAA 
disorders, homocystinuria) 
early onset peroxisomal 
disorders 
end state of all 
progressive WM disease 
metachromatic LD 
Krabbe disease 
LBSL 
Spares arcuate fibers 
Sjogren Larsson syndrome 
APBD 
ODDD 
Inborn errors of metabolism (PKU, 
FA2H-related disorders, adenylosiccuinate 
lyase deficiency, glutaric aciduria type II, 
mannosidosis) 
Later onset neurodegenerative disorders 
(e.g. NCL, Nieman Pick C (NB often early 
cerebral atrophy)) 
acquired disorders like periventricular 
leuomalacia and HIV-related 
encephalopathy 
L2-
hypoxyglutaric 
aciduria 
Canavan disease 
Keams-Sayre 
syndrome 
Propionic 
academia 
Urea cycle defects 
Ribose-5-
phosphate isomerase 
deficiency 
LTBL 
HDLS 
L2-hydroxyglutaric 
aciduria 
CRMCC 
Mitochondrial 
diseases 
Most infectious and 
inflammatory 
disorders (acquired) 
Inborn errors of 
metabolism such as 
urea cycle disorders 
CTX 
Peroxisomal 
disorders 
Alexander Disease 
LBSL 
ADLD 
Histiocytosis 
Early onset MSUD 
Premutation fragile 
X syndrome 
Heroin and cocaine 
toxicity 
FA2H related 
disorders (atrophy) 
Mitochondrial LEs 
91.781.771.761.751.741.731.7
LBSL 
LTBL 
HSBL 
ADLD 
Peroxisomal 
disorders 
APBD 
Wilson 
disease 
Alexander 
disease 
Leigh 
syndrome 
DRPLA 
Mitochondrial 
LEs 
Alexander 
disease 
Metachromatic 
LD 
Frontal variant 
of X-ALD 
HDLS 
Aicardi-
Goutieres 
Syndrome 
Laminin alpha-
2 deficiency 
Krabbe 
disease 
X-ALD 
Early onset 
peroxisomal 
disorders 
Neonatal 
hypoglycemia 
APBD 
Menkes 
disease 
Herpes 
simplex 
encephalitis 
Aicardi-
Goutieres 
syndrome 
Congenital 
CMV 
RNAse T2 
deficiency 
HDLS 
APBD 
L2-hydroxyglutaric aciduria 
LBSL 
HBSL 
Urea cycle disorders 
HMG-CoA lyase deficiency 
Histiocytosis 
Incontenitia pigmenti 
Vasculopathies (CADASIL, CARASIL, 
Fabry, Susac syndrome, arteriolosclerosis, 
vasculitis) 
Multiple sclerosis, neuromyelitic optica, 
acute disseminated encephalomyelitis 
progressive multifocal LE 
mitochondrial diseases 
Subacute Sclerosing Panencephalitis 
18q minus 
syndrome 
Sjogren Larsson 
syndrome 
RNAse T2 deficient 
LE 
Congenital CMV 
MPS 
Chromosomal 
abnormalities or 
genetic mosaicism 
Lowe syndrome 
PTEN-
associated 
disorders 
Histiocytosis 
Branched-chain 
amino acid 
disorders 
Figure 4. Continued.
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are negative or inconclusive, whole exome or genomic
sequencing may be used and these tests can be a signifi-
cant expense to the patient and health care systems. In
the current fiscal climate, a thorough study of cranial
MRI scans by a team of radiologists and clinicians
(metabolic geneticists, neurologists, etc.) may help in
streamlining the requirement of molecular/biochemical
tests.18 Average pricing estimates at our hospital suggest
that cranial MRI per patient costs <CAD$1000 com-
pared to the comprehensive LD panels and exome
sequencing, which cost approximately CAD$3000–5000
and CAD$5000, respectively.
The algorithm in this study promotes awareness
among radiologists and other specialists of the
different aspects of WMAs via MRI. Despite recording
low validity statistics, the algorithm should be viewed in
the context of the patient sample, the inclusion
criteria, and its limitations. Had the inclusion criteria
demanded for patients with multiple sequential MRI
scans that were a minimum of six months apart, the
algorithm would have been more applicable.
Similarly, the reduced utility of the algorithm in well-
managed and end-stage WMAs should be considered as
a limitation. Improvements to this study methodology
would include a larger patient sample and the
inclusion of more radiologists as well as other clinical
specialists. The addition of clinicians and >2 radiolo-
gists would allow for better quantification of inter-rater
reliability and reality simulation. The centre where this
study was conducted was a tertiary care centre, and it
would be of interest to see how future studies can be
performed at other health care levels with varying
resources. As a pilot study, the patient sample was sig-
nificantly heterogeneous in its different patient diagnos-
tic time points and range of WMAs. Future diagnostic
test values will be refined if narrowed down to a more
specific sample type, and having more non-specific
cases will produce more precise specificity and NPV
values.
Conclusion
It should be noted that this MRI algorithm is currently
the most systematic way to analyze MRI scans in the
context of WMAs. In some scenarios, MRI analysis
may result in a non-specific diagnosis for which differ-
ential diagnoses are difficult to pinpoint without full
molecular testing. However, even with non-specific con-
clusions, MRI pattern analyses are useful in excluding
many disorders that may not need to be tested for.10
Thorough MRI review can assist in deciding which spe-
cific molecular tests to follow-up with, which can have
decreased financial burden to the health care model and
benefits to patient comfort. This pilot study suggests
that this algorithm has significant clinical implications,
but much remains to be seen in terms of its shortcom-
ings, applications in clinical situations, potential
improvements and eventual introduction into clinical
settings.
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